Valve and Transcatheter Valve Programs

Blueprint for Disease-Centered Investments

This is a preview of restricted content.

Full access to this content is reserved for Cardiovascular Roundtable members. Log in now or learn more about Cardiovascular Roundtable.

About the Webconference

The FDA approval of transcatheter aortic valves has elicited unprecedented excitement and promises to alter the paradigm for treatment of valve disease. Yet pursuing this technology comes at a significant cost, including facility renovations and dedicated coordinators.

Operational investments may be even more noteworthy: persistent screening, multidisciplinary heart teams, and long-term follow-up care. This presentation provides structural and operational guidance on developing and optimizing valve centers, including detailed profiles from leading centers.

Presenter: Megan Tooley

View the On-Demand Presentation

Watch the video Stream video recording

Download PDF Download PDF

Topics: Cardiovascular, Service Lines, Cardiac Cath, Strategy, Market Trends